肌肉骨骼领域的合作与授权协议（2016-2026）

肌肉骨骼领域併购的权威基准

我们在肌肉骨骼领域的合作涵盖了广泛的领域，包括退化性疾病、发炎性疾病和创伤相关疾病，我们的交易结构反映了多样化的治疗方法，例如药物、生物製药和整形外科干预。

本报告对肌肉骨骼领域的 509 项合作与许可协议进行了全面系统的分析，清楚地展示了伙伴关係在整个市场中的设计、谈判和执行方式，并以证据为基础进行了阐述。

充分了解市场标准。

本报告将帮助您准确了解肌肉骨骼领域的交易结构，并使您能够：

• 自信地对标类似交易
• 对相关交易中的预付款、里程碑付款和特许权使用费结构进行详细分析。
• 设定切合实际的市场参数
• 您可以深入了解交易条款如何因阶段、资产类型和合作伙伴情况而异。
• 支持实证评估和结构性决策
• 我们将根据实际交易数据进行内部讨论，而不是根据假设。
• 了解主要企业如何处理交易
• 在临床多样化和以治疗为中心的环境中，可视化合作伙伴行为和重复交易模式。
• 全面了解交易结构和执行情况
• 本报告超越了表面的交易数据，提供了对底层合约文件的访问，使您能够详细了解实际合约是如何构建的。

这包括：

• 授予和保留的权利
• 负责开发和商业化
• 财务结构和支付触发机制
• 关键合约条款和保障措施
• 这种程度的透明度对于了解肌肉骨骼疾病（尤其是慢性疾病和干预主导的治疗方法）的伙伴关係如何分配价值、风险和控制至关重要。
• 它旨在为实际的业务发展和策略制定提供帮助。

本报告主要广泛用于以下用途：

• 建置和基准测试实际交易
• 在清晰的市场环境下准备谈判
• 合作机会及目的地评估
• 支援稳健且引人注目的数据驱动型内部策略
• 内容
• 肌肉骨骼领域共有 509 项合作关係和授权协议
• 财务条款，包括预付款、里程碑付款和版税（如有揭露）。
• 可全文搜寻的合约目录（依公司、治疗领域及技术分类）
• 可直接查阅向美国证券交易委员会提交的合约和原始文件。
• 交易趋势分析、关键交易和活跃负责人
• 关于肌肉骨骼领域交易的可靠、基于证据的参考资料。
• 本报告结合全面的交易报告和合约层面的深入分析，为如何在肌肉骨骼领域建立、谈判和评估伙伴关係提供了可靠的、基于证据的参考资料。

目录

执行摘要

第一章：引言

第二章：肌肉骨骼健康保险交易趋势

• 介绍
• 长期存在的肌肉骨骼伙伴关係
• 肌肉骨骼领域的合作关係（按交易类型划分）
• 肌肉骨骼领域的合作伙伴关係（按行业划分）
• 肌肉骨骼领域的合作（依发展阶段划分）
• 肌肉骨骼领域的合作（依技术类型划分）
• 肌肉骨骼系统领域的合作（依治疗适应症划分）

第三章 肌肉骨骼伙伴关係中的财务术语

• 介绍
• 揭露肌肉骨骼伙伴关係的财务条款
• 肌肉骨骼伙伴关係的关键价值
• 预付肌肉骨骼疾病治疗费用
• 肌肉骨骼系统相关合约的里程碑付款
• 肌肉骨骼相关产品的特许权使用费率

第四章：肌肉骨骼系统领域的主要交易与相关人员

• 介绍
• 在肌肉骨骼系统的协调上最为活跃
• 肌肉骨骼领域最活跃交易员名单
• 肌肉骨骼相关产品的优惠资讯（依价格排序）

第五章：肌肉骨骼系统合约文件清单

• 介绍
• 肌肉骨骼系统领域的合作协议（如有）

第六章：透过治疗标靶在肌肉骨骼系统中进行交易

• 介绍
• 基于肌肉骨骼治疗标靶的交易
• 特价优惠列表
• 交易清单 - 公司特定肌肉骨骼系统相关交易 (AZ)
• 交易清单 - 按技术类型分類的肌肉骨骼系统相关交易
• 交易类型的定义
• 关于这家研究公司
• Current Partnering
• 目前合约
• 理想合作伙伴最新报告的标题

The definitive benchmark for musculoskeletal dealmaking

Musculoskeletal partnering spans a range of degenerative, inflammatory, and injury-related conditions, with deal structures reflecting diverse treatment approaches across pharmaceuticals, biologics, and orthopedic interventions.

This report provides a comprehensive and structured analysis of 509 musculoskeletal collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how musculoskeletal deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a clinically diverse and treatment-focused landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within musculoskeletal partnerships, particularly across chronic conditions and intervention-driven treatment approaches.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 509 musculoskeletal collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for musculoskeletal dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how musculoskeletal partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in musculoskeletal dealmaking

• 2.1. Introduction
• 2.2. Musculoskeletal partnering over the years
• 2.3. Musculoskeletal partnering by deal type
• 2.4. Musculoskeletal partnering by industry sector
• 2.5. Musculoskeletal partnering by stage of development
• 2.6. Musculoskeletal partnering by technology type
• 2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 - Financial deal terms for musculoskeletal partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for musculoskeletal partnering
• 3.3. Musculoskeletal partnering headline values
• 3.4. Musculoskeletal deal upfront payments
• 3.5. Musculoskeletal deal milestone payments
• 3.6. Musculoskeletal royalty rates

Chapter 4 - Leading musculoskeletal deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in musculoskeletal partnering
• 4.3. List of most active dealmakers in musculoskeletal
• 4.4. Top musculoskeletal deals by value

Chapter 5 - Musculoskeletal contract document directory

• 5.1. Introduction
• 5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 - Musculoskeletal dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by musculoskeletal therapeutic target
• Deal directory
• Deal directory - Musculoskeletal deals by company A-Z
• Deal directory - Musculoskeletal deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Musculoskeletal partnering since 2016
• Figure 2: Musculoskeletal partnering by deal type since 2016
• Figure 3: Musculoskeletal partnering by industry sector since 2016
• Figure 4: Musculoskeletal partnering by stage of development since 2016
• Figure 5: Musculoskeletal partnering by technology type since 2016
• Figure 6: Musculoskeletal partnering by indication since 2016
• Figure 7: Musculoskeletal deals with a headline value
• Figure 8: Musculoskeletal deals with upfront payment values
• Figure 9: Musculoskeletal deals with milestone payment
• Figure 10: Musculoskeletal deals with royalty rates
• Figure 11: Active musculoskeletal dealmaking activity since 2016
• Figure 12: Top musculoskeletal deals by value since 2016